Cladribine treatment for ms preserves the differentiative capacity of subsequently generated monocytes, whereas its administration in vitro acutely influences monocyte differentiation but not microglial activation

HIGHLIGHTS

• who: Tiago Medeiros-Furquim from the Heinrich Heine University of Du00fcsseldorf, Germany have published the article: Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation, in the Journal: (JOURNAL)
• what: This study showed that the pre-treatment with 60 nM cladribine significantly reduced the secretion of IL-6 and TNF-a (but not other analyzed cytokines) and also the phagocytic activity of MCSF-derived MDMs when challenged with LPS.
• how: For the differentiation of monocytes from MS . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.